View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 6, 2021updated 25 Nov 2021 9:50am

Zymeworks and ALX dose subject in Phase Ib/II cancer therapy trial 

The trial will evaluate the safety and efficacy of zanidatamab plus evorpacept in patients with HER2-expressing cancers.

Zymeworks and ALX Oncology have dosed the first subject in the Phase Ib/II clinical trial of Zanidatamab plus evorpacept (ALX148) in patients with advanced human epidermal growth factor receptor 2 (HER2)-expressing breast cancer and various solid tumours.

Zanidatamab is a HER2‑targeted bispecific antibody of Zymeworks, while evorpacept is a Cluster of Differentiation 47 (CD47) blocker of ALX.

Based on the Azymetric platform of Zymeworks, zanidatamab can attach concurrently to two non-overlapping epitopes of HER2, which is called biparatopic binding.

Evorpacept is a CD47 blocking treatment that merges an increased-affinity CD47 binding domain with an Fc domain that is not activated.

The open-label, multicentre trial carried out by Zymeworks will assess the safety and efficacy of zanidatamab plus evorpacept in patients with advanced HER2-positive breast cancer, HER2-low breast cancer and other non-breast HER2-expressing solid tumours.

This partnership builds on the potential antitumor activity of evorpacept plus zanidatamab demonstrated in trials involving advanced HER2‑positive gastric or gastroesophageal junction cancer patients.

Adding CD47 blockade aids in boosting the immunotherapeutic properties of zanidatamab.

Furthermore, it can potentially be useful to a wide range of patients, including those with advanced HER2‑expressing breast cancer and other HER2‑expressing tumours.

Zymeworks noted that zanidatamab, in combination with evorpacept, can possibly boost the immune clearance of HER2-expressing cancer cells.

The treatment can merge a biparatopic antibody capable of binding at increased density as compared to monospecific antibodies with a molecule that hinders CD47 on the same targeted tumour cells.

Zanidatamab is currently being analysed in various Phase I, Phase II and pivotal trials across the globe as a targeted therapy option for HER2-expressing solid tumour patients.

ALX is evaluating evorpacept along with various anti-tumour agents in multiple international Phase I as well as Phase II trials for a variety of hematologic and solid cancers.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy